This category covers biotechnology and pharmaceutical companies developing therapies targeting pyroptosis and gasdermin pathways for the treatment of Alzheimer's disease. Pyroptosis is a caspase-1 dependent inflammatory cell death pathway characterized by gasdermin D (GSDMD) pore formation that leads to cell swelling, membrane rupture, and release of pro-inflammatory cytokines including IL-1β and IL-18.
The pyroptosis pathway is increasingly recognized as a key contributor to neurodegeneration in AD:
Companies in this space pursue several mechanisms:
- Caspase-1 inhibition — prevent GSDMD cleavage upstream
- NLRP3 inflammasome inhibition — block inflammasome assembly
- GSDMD inhibition — target the executioner molecule directly
- IL-1β/IL-18 blockade — downstream cytokine inhibition
Direct inhibition of caspase-1 prevents GSDMD cleavage and pro-inflammatory cytokine maturation. This is the most upstream intervention point in the pyroptosis pathway.
Block assembly of the NLRP3 inflammasome complex, preventing caspase-1 activation. This approach offers broader anti-inflammatory effects beyond just pyroptosis blockade.
Direct targeting of GSDMD to prevent pore formation while preserving beneficial inflammasome signaling. Includes small molecules, peptides, and antibody-based approaches.
Downstream inhibition of released pro-inflammatory cytokines. Limited by concerns about CNS penetration but approved drugs offer repurposing opportunities.
¶ Eli Lilly and Company
- Focus: NLRP3/GSDMD-targeted small molecules
- Approach: Internal discovery program targeting neuroinflammation
- Related Programs: Multiple CNS inflammation partnerships
- Notes: One of the largest pharmaceutical companies with significant AD pipeline including donanemab (anti-amyloid) and other disease-modifying approaches
- Related Page: Eli Lilly
- Focus: Inflammasome modulators and cytokine inhibitors
- Approach: Partnerships and internal programs targeting neuroinflammation
- Notes: Has exploration programs in NLRP3 inhibition space; established CNS capabilities
- Related Page: Pfizer
- Focus: NLRP3 inflammasome and IL-1 pathway inhibition
- Approach: Acquisitions and partnerships in inflammation therapeutics
- Notes: Strong inflammation portfolio with strategic interest in neurodegeneration; BMS-986253 (anti-IL-8) in development
- Related Page: Bristol Myers Squibb
- Focus: GSDMD-targeted small molecules
- Lead Candidate: ZNL-0801 (research program)
- Indication: Alzheimer's disease
- Stage: Discovery/Preclinical
- Mechanism: Direct GSDMD inhibitor designed to block pyroptotic pore formation
- Notes: Novel approach directly targeting the executioner of pyroptosis; company known for targeted oncology therapies expanding into neurodegeneration
- Focus: NLRP3 inflammasome inhibition
- Lead Candidate: NT-0796
- Indication: Alzheimer's disease
- Stage: Phase 1/2
- Mechanism: Brain-penetrant NLRP3 small molecule inhibitor
- Notes: First-in-class oral therapy targeting neuroinflammation; backed byflagship pioneering
- Related Page: Nodthera
- Focus: NLRP3 inflammasome inhibition
- Lead Candidate: Dapansutrile (OLT1177)
- Indication: Alzheimer's disease
- Stage: Phase 2
- Mechanism: Oral NLRP3 inhibitor with established safety profile in inflammatory conditions
- Notes: Well-characterized small molecule with broad anti-inflammatory effects; has shown efficacy in multiple inflammatory conditions
- Related Page: Olatec Therapeutics
- Focus: NLRP3 and GSDMD modulation
- Approach: Small molecule programs targeting inflammasome pathways
- Stage: Preclinical
- Notes: Founded by Atlas Venture; acquired by BMS in 2021 but maintains independent operations; focused on innate immune pathways
- Related Page: IFM Therapeutics
- Focus: GSDMD inhibition (repurposed)
- Indication: ALS, exploratory for AD
- Stage: Observational/Preclinical
- Mechanism: Known GSDMD inhibitor; blocks pyroptosis execution
- Notes: Generic drug with established safety profile; being explored in neurodegenerative diseases
- Focus: GSDMD modulation
- Indication: Multiple Sclerosis, exploratory for AD
- Stage: Approved for MS; Phase 2 in AD
- Mechanism: Has shown GSDMD inhibition properties; immunomodulatory effects
- Notes: Tecfidera is approved for MS; company exploring neurological applications
- Related Page: Biogen
¶ Antibody-Based Approaches
- Focus: IL-1β antibody
- Indication: Alzheimer's disease (exploratory)
- Stage: Phase 2
- Mechanism: Monoclonal antibody targeting IL-1β, downstream of pyroptosis
- Notes: Approved for autoimmune conditions; CNS penetration remains a concern
- Focus: IL-1R antagonist
- Indication: Inflammatory conditions, exploratory for neurodegeneration
- Stage: Phase 2
- Mechanism: Recombinant IL-1 receptor antagonist
- Notes: Established safety profile; limited CNS penetration
- Focus: NLRP3 and cGAS-STING inhibition
- Lead Candidates: VENT-01, VENT-02
- Stage: Discovery
- Mechanism: Novel small molecule inflammasome inhibitors
- Notes: Precision immunology company targeting innate immune pathways
- Related Page: Ventus Therapeutics
- Focus: Neuroinflammation modulation
- Approach: Platform targeting multiple inflammatory pathways
- Stage: Discovery
- Notes: Focused on microglial modulation and neuroinflammation
| Company |
Drug/Mechanism |
Target |
Indication |
Stage |
| Eli Lilly |
Small molecule program |
NLRP3/GSDMD |
AD |
Discovery |
| Pfizer |
Inflammasome modulators |
NLRP3 |
AD |
Research |
| BMS |
NLRP3 program |
NLRP3 |
Neurodegeneration |
Preclinical |
| Zentalis |
ZNL-0801 |
GSDMD |
AD |
Discovery |
| Nodthera |
NT-0796 |
NLRP3 |
AD |
Phase 1/2 |
| Olatec |
Dapansutrile |
NLRP3 |
AD |
Phase 2 |
| IFM Therapeutics |
Small molecules |
NLRP3/GSDMD |
Neurodegeneration |
Preclinical |
| Disulfiram (repurposed) |
Generic |
GSDMD |
AD/ALS |
Observational |
| Biogen |
Dimethyl fumarate |
GSDMD |
AD |
Phase 2 |
| Novartis |
Canakinumab |
IL-1β |
AD |
Phase 2 |
| Ventus Therapeutics |
VENT-01 |
NLRP3 |
Neurodegeneration |
Discovery |
The involvement of pyroptosis in AD is supported by multiple lines of evidence:
-
Amyloid-beta activation: Aβ directly activates NLRP3 inflammasome in microglia, triggering caspase-1 activation and GSDMD cleavage
-
Tau pathology synergy: Phosphorylated tau promotes GSDMD cleavage, creating a feed-forward loop between tau pathology and pyroptotic cell death
-
Neuronal vulnerability: Neurons in AD-vulnerable regions show enhanced susceptibility to pyroptotic death
-
Microglial dysfunction: Microglial pyroptosis leads to loss of supportive functions and creates chronic neuroinflammation
-
Genetic links: NLRP3 and related gene variants are associated with AD risk
Blocking pyroptosis offers dual benefits:
- Prevent cell death: Block GSDMD-mediated neuronal loss
- Reduce inflammation: Prevent release of IL-1β, IL-18, and other pro-inflammatory mediators
This makes pyroptosis inhibition an attractive disease-modifying approach for AD.